Prospective clinic cohorts measuring depression (PHQ‑9), anxiety (GAD‑7) and suicidal ideation in the first year after starting puberty blockers or gender‑affirming hormones provide important signals but cannot on their own establish short‑term causal benefit because of selection, timing, and reporting biases. Policymakers and courts should require robustness maps (negative controls, sibling/panel designs, sensitivity analyses) before treating early observational improvements as definitive evidence for broad policy action.
— This reframes debates about pediatric gender‑affirming care away from single observational headlines toward stronger evidentiary standards that have immediate regulatory and legal consequences.
2023.01.04
88% relevant
The study’s two‑year follow‑up connects to the existing point that short‑term clinic cohort improvements cannot on their own settle causality or policy; the NEJM data feed that debate by supplying widely cited early‑outcome numbers that courts and regulators may lean on without robustness maps.
2022.01.04
100% relevant
Tordoff et al., JAMA Netw Open 2022 cohort study measuring PHQ‑9/GAD‑7 and self‑reported suicidal ideation across the first year after care initiation (puberty blockers and gender‑affirming hormones).
← Back to All Ideas